ICU sedation, delirium & recovery

Dexmedetomidine and Propofol Sedation in Critically Ill Patients and Dose-associated 90-Day Mortality: A Secondary Cohort Analysis of a Randomized Controlled Trial (SPICE III)

Am J Respir Crit Care MedPublished Secondary analysis of the SPICE III randomised trial

Primary result · 90-day mortality, escalating propofol dose at steady dexmedetomidine (younger patients)Result — go to the resultHazard ratio 0.59 95% CI 0.43–0.78

Authors' conclusion

In patients ⩽65 years of age sedated with dexmedetomidine and propofol combination, preferentially increasing the dose of propofol was associated with decreased adjusted 90-day mortality.

Study context

Population
Critically ill patients randomised in SPICE III to dexmedetomidine and given supplemental propofol
Participants
1,177 patients
Comparison
Escalating propofol vs dexmedetomidine infusion rates in combination sedation, stratified by age (>65 vs ⩽65 yr)
  • ⩽65 yrn = 598
Methodological detailssecondary cohort analysis, double stratification analysis, multivariable Cox regression
  • Secondary cohort analysis
  • Double stratification analysis
  • Multivariable Cox regression

Primary result

As reported in the abstract

90-day mortality, escalating propofol dose at steady dexmedetomidine (younger patients) · 90 days

Hazard ratio

0.59

95% CI 0.43–0.78

P < 0.0001

Escalating propofol infusion rate
HR 0.59 (95% CI 0.43–0.78); P < 0.0001

Further findings

90-day mortality, escalating dexmedetomidine dose (younger patients)

HR (95% CI)P value
Escalating dexmedetomidine infusion rateYounger patients; adjusted · multivariable regression1.30 (1.03–1.65)P = 0.029

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Dexmedetomidine and Propofol Sedation in Critically Ill Patients and Dose-associated 90-Day Mortality: A Secondary Cohort Analysis of a Randomized Controlled Trial (SPICE III). Am J Respir Crit Care Med. Published 1 April 2023. doi:10.1164/rccm.202206-1208oc

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.